Total Payments
$127,833
2024 Payments
$428.84
Companies
44
Transactions
105
Medicare Patients
19,649
Medicare Billing
$5.9M
Payment Breakdown by Category
Research$125,697 (98.3%)
Food & Beverage$2,111 (1.7%)
Education$24.69 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $125,697 | 6 | 98.3% |
| Food and Beverage | $2,111 | 97 | 1.7% |
| Education | $24.69 | 2 | 0.0% |
Payments by Type
Research
$125,697
6 transactions
General
$2,136
99 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $125,730 | 8 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $241.33 | 12 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $198.81 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $123.77 | 6 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $100.80 | 2 | $0 (2018) |
| Genentech USA, Inc. | $99.81 | 6 | $0 (2021) |
| Daiichi Sankyo Inc. | $91.31 | 4 | $0 (2024) |
| Tactile Systems Technology Inc | $89.64 | 3 | $0 (2022) |
| PUMA BIOTECHNOLOGY, INC. | $79.86 | 4 | $0 (2024) |
| PFIZER INC. | $75.64 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $428.84 | 19 | Daiichi Sankyo Inc. ($74.67) |
| 2023 | $352.67 | 12 | AstraZeneca Pharmaceuticals LP ($126.11) |
| 2022 | $318.18 | 14 | Tactile Systems Technology Inc ($89.64) |
| 2021 | $158.09 | 9 | GENZYME CORPORATION ($23.37) |
| 2020 | $66.65 | 4 | EMD Serono, Inc. ($24.89) |
| 2019 | $10,538 | 15 | Celgene Corporation ($10,243) |
| 2018 | $48,125 | 11 | Celgene Corporation ($47,959) |
| 2017 | $67,845 | 21 | Celgene Corporation ($67,496) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $29.27 | General |
| Category: Rare Disease | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.38 | General |
| Category: Hematology/Oncology | ||||||
| 07/26/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Oncology | ||||||
| 07/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $25.43 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $25.50 | General |
| Category: Oncology | ||||||
| 06/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $22.87 | General |
| 01/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.01 | General |
| 11/15/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Oncology | ||||||
| 10/25/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $31.12 | General |
| Category: Oncology | ||||||
| 10/12/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Oncology | ||||||
| 09/18/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Oncology | ||||||
| 08/30/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 | Celgene Corporation | $66,033 | 2 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $47,959 | 2 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $10,243 | 1 |
| AG-221-AML-004 | Celgene Corporation | $1,463 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 64 | 3,336 | 63,923 | $3.9M | $779,126 |
| 2022 | 61 | 3,990 | 101,123 | $4.5M | $976,227 |
| 2021 | 82 | 6,323 | 223,574 | $9.5M | $2.2M |
| 2020 | 85 | 6,000 | 231,533 | $9.4M | $2.0M |
Total Patients
19,649
Total Services
620,153
Medicare Billing
$5.9M
Procedure Codes
292
All Medicare Procedures & Services
292 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 9,600 | $1.4M | $415,417 | 29.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,604 | $400,968 | $53,550 | 13.4% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 1,820 | $353,080 | $39,336 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 216 | 367 | $98,840 | $33,237 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 280 | 519 | $94,121 | $32,581 | 34.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 36 | 33,000 | $165,000 | $28,972 | 17.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 98 | 283 | $236,155 | $28,758 | 12.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 1,440 | $102,180 | $26,622 | 26.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 34 | 173 | $12,110 | $12,191 | 100.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 350 | 1,467 | $51,345 | $11,139 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 117 | 205 | $62,320 | $9,769 | 15.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 71 | $279,598 | $9,499 | 3.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 252 | 859 | $53,258 | $8,856 | 16.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 272 | 677 | $12,863 | $5,671 | 44.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 2,520 | $52,920 | $5,637 | 10.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 79 | 402 | $42,210 | $4,821 | 11.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 55 | 152 | $23,104 | $3,417 | 14.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 100 | 252 | $14,616 | $3,367 | 23.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 12 | 2,340 | $21,060 | $3,194 | 15.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 66 | 77 | $9,735 | $3,020 | 31.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 34 | 45 | $13,825 | $2,762 | 20.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 45 | 303 | $16,362 | $2,761 | 16.9% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 54 | 133 | $16,492 | $2,712 | 16.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 106 | $19,994 | $2,338 | 11.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 17 | $6,176 | $2,126 | 34.4% |
About Dr. Heather Brooks, MD
Dr. Heather Brooks, MD is a Hematology & Oncology healthcare provider based in Christiansburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1295947992.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heather Brooks, MD has received a total of $127,833 in payments from pharmaceutical and medical device companies, with $428.84 received in 2024. These payments were reported across 105 transactions from 44 companies. The most common payment nature is "" ($125,697).
As a Medicare-enrolled provider, Brooks has provided services to 19,649 Medicare beneficiaries, totaling 620,153 services with total Medicare billing of $5.9M. Data is available for 4 years (2020–2023), covering 292 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Christiansburg, VA
- Active Since 05/04/2007
- Last Updated 02/18/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1295947992
Products in Payments
- Revlimid (Drug) $124,234
- Idhifa (Drug) $1,463
- ENHERTU (Biological) $126.11
- KEYTRUDA (Biological) $100.80
- Enhertu (Drug) $91.31
- Flexitouch Plus (Device) $89.64
- KISQALI (Drug) $68.85
- Xtandi (Drug) $55.19
- OPDIVO (Biological) $55.09
- ELIQUIS (Drug) $54.03
- IMFINZI (Drug) $50.72
- PLUVICTO (Drug) $49.93
- PIQRAY (Drug) $47.12
- FOUNDATIONONE (Device) $45.97
- NERLYNX (Drug) $44.18
- OPDUALAG (Drug) $44.12
- LIBTAYO (Biological) $40.93
- ICLUSIG (Drug) $39.56
- JAKAFI (Drug) $38.82
- Optune (Device) $38.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.